The global atherectomy devices market is on a strong growth path, projected to reach US$ 2,028.3 million by 2032, up from US$ 964.3 million in 2023, with a compound annual growth rate (CAGR) of 8.61% from 2024 to 2032. Key factors driving this growth include the rising prevalence of peripheral artery disease (PAD), technological advancements in medical devices, an aging global population, and an increased preference for minimally invasive procedures. Additionally, favorable reimbursement policies and the growing healthcare infrastructure in emerging economies are further bolstering the market expansion.
Request a free sample copy of the report: https://www.renub.com/atherectomy-devices-market-p.php
Atherectomy Devices Overview
Atherectomy devices are specialized medical tools designed to treat atherosclerosis, a condition in which fatty deposits or plaques accumulate in the arteries, restricting blood flow and potentially leading to heart attacks or strokes. These devices work by removing or reducing arterial plaque, helping to restore proper blood circulation.
A typical atherectomy procedure involves a catheter being inserted through a small incision, often in the groin or wrist, and guided into the affected artery. The atherectomy device then either cuts, grinds, or vaporizes the plaque, which is either flushed away or collected in a filter to prevent embolization. This minimally invasive procedure not only improves blood flow but also alleviates symptoms such as leg pain, fatigue, and chest discomfort, ultimately enhancing the patient’s cardiovascular health.
Key Drivers of the Atherectomy Devices Market
- Rising Incidence of Peripheral Artery Disease (PAD)
The global prevalence of PAD, especially among older adults and those with comorbidities like diabetes and obesity, is a major factor driving the demand for atherectomy devices. In the U.S. alone, PAD affects approximately 8 to 12 million people, with a significant portion of the population over the age of 50 being diagnosed with the condition. Atherectomy devices offer a highly effective, minimally invasive treatment option for PAD patients by directly removing arterial plaque and improving blood circulation, which reduces the risk of complications like heart attacks and strokes.
- Preference for Minimally Invasive Procedures
Minimally invasive surgical techniques are becoming increasingly popular due to their many advantages over traditional open surgeries, such as reduced trauma, shorter recovery times, and a lower risk of complications. Atherectomy procedures, being minimally invasive, help meet the growing demand for less intrusive treatment options. As healthcare professionals and patients prioritize quicker recovery and lower risk, the appeal of atherectomy devices is rising.
- Technological Advancements
Technological innovation in atherectomy devices is a major growth driver. Modern atherectomy systems now feature enhanced imaging and navigation technologies that provide better precision and control during procedures, thereby reducing the risk of damage to surrounding tissues and improving patient outcomes. Furthermore, advances such as the miniaturization of devices have made the procedures less invasive, resulting in faster recovery times and fewer complications. The incorporation of drug-eluting technologies and other specialized features continues to enhance the effectiveness of these devices.
In November 2021, Royal Philips introduced its Nexcimer laser system for both peripheral and coronary artery applications, providing a more efficient and user-friendly solution for atherectomy treatments. These innovations contribute to the continued growth of the market.
- Aging Population
As the global population ages, the incidence of cardiovascular diseases, including PAD, is increasing. The aging population is more susceptible to atherosclerosis and other cardiovascular conditions, leading to a higher demand for atherectomy devices that can provide effective treatment with reduced risks compared to traditional surgery. This demographic shift is expected to drive the atherectomy devices market, particularly in developed economies.
- Improved Healthcare Infrastructure and Reimbursement Policies
In emerging economies, the development of healthcare infrastructure, alongside favorable reimbursement policies, is increasing access to atherectomy procedures. Governments and private insurers are increasingly supporting the adoption of minimally invasive treatments, making atherectomy devices more accessible to a larger segment of the population.
North America: Leading the Atherectomy Devices Market
North America is expected to dominate the atherectomy devices market due to several factors, including a high prevalence of cardiovascular diseases, well-established reimbursement frameworks, and the availability of advanced atherectomy devices approved by regulatory bodies like the U.S. FDA. Cardiovascular diseases, including coronary artery disease (CAD) and PAD, are among the leading causes of death in the United States. As a result, there is a substantial demand for atherectomy procedures as part of comprehensive cardiovascular treatment plans.
In addition to the high disease burden, the favorable reimbursement policies in North America make atherectomy treatments more accessible to patients, contributing to market growth. For example, in October 2021, Becton, Dickinson, and Company (BD) received FDA approval for expanded indications for its Rotarex Atherectomy System, enhancing its market penetration and boosting demand for atherectomy devices in the U.S.
Key Companies in the Global Atherectomy Devices Market
Leading players in the atherectomy devices market include:
- Boston Scientific Corporation, Inc.
- Abbott Laboratories
- Medtronic plc
- Cardinal Health
- Terumo Corporation
- Integer Holdings Corporation
- Becton, Dickinson and Company
- AngioDynamics, Inc.
These companies are involved in the development, manufacturing, and commercialization of advanced atherectomy devices and technologies. Ongoing innovations, along with strategic partnerships and acquisitions, are expected to propel further growth in the market.
Notable News in the Atherectomy Devices Industry
- November 2023: Cardinal Health launched the SmartGown EDGE Breathable Surgical Gown with ASSIST Instrument Pockets in the U.S. The product aims to provide surgical teams with safe and practical instrument access, further improving procedural efficiency in the operating room.
- August 2022: AngioDynamics, Inc. received 510(k) approval for the Auryon Atherectomy System, expanding its indication to include arterial thrombectomy. This approval enables the device to be used for a broader range of vascular procedures.
- February 2022: RA Medical Systems announced the enrollment of 95 individuals in its critical clinical trial to assess the safety and efficacy of the DABRA excimer laser system for peripheral artery disease. The results of this trial are expected to bolster the adoption of the system in clinical settings.
Related Report :
Bariatric Surgery Devices Market
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: mailto:rajat@renub.com
